glycogen synthase kinase-3beta inhibitors (Amphora)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameglycogen synthase kinase-3beta inhibitors (Amphora)
Drug Alias NameGsk-3beta inhibitors (Amphora)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitors
TargetsGlycogen synthase kinase-3 beta
Therapy Area/IndicationsPainNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmphora Discovery Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmphora Discovery Corp
Active IndicationsN/A
Inactive IndicationsPainNerve Degeneration

Other Information

ATC CodeN/A
Related LinksN/A